Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer

Research Articles



Ovarian cancer is associated with high mortality due to presentation at advanced stage and high recurrence following treatment with chemotherapy. Most of the prognostic variables in ovarian cancer, including stage and residual disease, are amenable for assessment only after surgery. Currently there are no established preoperative markers including, CA-125, that can predict overall survival in patients with ovarian cancer. The aim of our study was to evaluate the prognostic significance of the preoperative haematological markers platelet lymphocyte ratio (PLR) and neutrophil lymphocyte ratio (NLR) in patients with ovarian cancer.


Preoperative PLR and NLR were evaluated in 235 patients undergoing surgery for ovarian cancer. The prognostic significance of both markers was then determined by both uni- and multivariate analytical methods.


High preoperative PLR (p<0.001) and NLR (p=0.001) were significantly associated with poor survival using univariate Cox survival analysis. The median overall survival in patients with a PLR of <300 was 37.4 months (95%CI 26.1–48.7) and 14.5 months (95%CI 11.7–17.2) in those with a PLR of >300. PLR (p=0.03) but not NLR (p=0.575) retained its significance as a prognostic marker on multivariate Cox’s regression analysis, along with stage (p<0.001) and residual disease (p=0.015).


We have shown for the first time that PLR is a novel independent prognostic marker in patients with ovarian cancer.


Platelet lymphocyte ratio Ovarian cancer Prognostic marker 


  1. 1.
    Cancer Research UK (2006) Ovarian cancer incidence statistics. Cancer Research UK. Available from:
  2. 2.
    Horner MJ, Ries LAG, Krapcho M et al (eds) (2009) SEER cancer statistics review, 1975–2006. Available from:
  3. 3.
    Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRefGoogle Scholar
  4. 4.
    Marchetti C, Pisano C, Facchini G et al (2009) First-line treatment of advanced ovarian cancer: current research and perspectives. Exp Rev Anticancer Ther 10:47–60CrossRefGoogle Scholar
  5. 5.
    Ozols RF (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17[Suppl 5]:v181–187PubMedCrossRefGoogle Scholar
  6. 6.
    Gadducci A, Cosio S, Tana R, Genazzani AR (2009) Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 69:12–27PubMedCrossRefGoogle Scholar
  7. 7.
    Bast RC Jr, Badgwell D, Lu Z et al (2005) New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15[Suppl 3]:274–281CrossRefGoogle Scholar
  8. 8.
    Gupta D, Lis CG (2009) Role of CA125 in predicting ovarian cancer survival: a review of the epidemiological literature. J Ovarian Res 2:13PubMedCrossRefGoogle Scholar
  9. 9.
    Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899PubMedCrossRefGoogle Scholar
  10. 10.
    Hefler LA, Concin N, Hofstetter G et al (2008) Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 14:710–714PubMedCrossRefGoogle Scholar
  11. 11.
    Li AJ, Madden AC, Cass I et al (2004) The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 92:211–214PubMedCrossRefGoogle Scholar
  12. 12.
    Bozkurt N, Yuce K, Basaran M et al (2004) Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer. Obstet Gynecol 103):82–85PubMedCrossRefGoogle Scholar
  13. 13.
    Bishara S, Griffin M, Cargill A et al (2008) Pretreatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 138:71–75PubMedCrossRefGoogle Scholar
  14. 14.
    den Ouden M, Ubachs JM, Stoot JE, van Wersch JW (1997) Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol 72:73–77CrossRefGoogle Scholar
  15. 15.
    Cho H, Hur HW, Kim SW et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58:15–23PubMedCrossRefGoogle Scholar
  16. 16.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545PubMedCrossRefGoogle Scholar
  17. 17.
    Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRefGoogle Scholar
  18. 18.
    Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A (2007) Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 18:171–182PubMedCrossRefGoogle Scholar
  19. 19.
    Chen LL, Ye F, Lü WG et al (2009) Evaluation of immune inhibitory cytokine profi les in epithelial ovarian carcinoma. J Obstet Gynaecol Res 35:212–218PubMedCrossRefGoogle Scholar
  20. 20.
    Fumagalli LA, Vinke J, Hoff W et al (2003) Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26:394–402PubMedCrossRefGoogle Scholar
  21. 21.
    Fogar P, Sperti C, Basso D et al (2006) Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 32:22–28PubMedCrossRefGoogle Scholar
  22. 22.
    Menczer J, Schejter E, Geva D et al (1998) Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 19:82–84Google Scholar
  23. 23.
    Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009) The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet 279:53–56PubMedCrossRefGoogle Scholar
  24. 24.
    Zacharski LR, Memoli VA, Ornstein DL et al (1993) Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 85:1225–1230PubMedCrossRefGoogle Scholar
  25. 25.
    Bastida E, Ordinas A, Giardina SL, Jamieson GA (1982) Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 42:4348–4352PubMedGoogle Scholar
  26. 26.
    Holmes CE, Levis JE, Ornstein DL (2009) Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 26:653–661PubMedCrossRefGoogle Scholar
  27. 27.
    Aliustaoglu M, Bilici A, Ustaalioglu BB et al (2010) The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 27:1060–1065PubMedCrossRefGoogle Scholar
  28. 28.
    Ong SL, Garcea G, Thomasset SC et al (2008) Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic centre with review of the literature. HPB (Oxford) 10:446–458Google Scholar
  29. 29.
    Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxelcisplatin chemotherapy: a prospective study. BMC Cancer 10:50PubMedCrossRefGoogle Scholar
  30. 30.
    Smith RA, Bosonnet L, Raraty M et al (2009) Preoperative platelet-lymphocyte ratio is an independent signifi cant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2011

Authors and Affiliations

  • Viren Asher
    • 1
  • Joanne Lee
    • 2
  • Anni Innamaa
    • 1
  • Anish Bali
    • 2
  1. 1.School of Graduate Medicine and HealthRoyal Derby HospitalDerbyUK
  2. 2.Royal Derby HospitalDerbyUK

Personalised recommendations